So according to OSL release , the survival data are in line with what would be expected with neoadjuvant chemotherapy.
- but in Panco trial these patients received neoadjuvant chemo plus oncosil device
- so isn’t this just saying if results are in line with neoadjuvant chemo as OSL state, the device doesn’t add any further benefit over what you’d expect with chemo??
- they should really present the median survival for all 10
- to me these results are ok, and obviously good for the 6 who’ve made it this far- but overall not stand-out
- why haven’t they provided updated survival for the whole study?
So according to OSL release , the survival data are in line with...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
0.001(4.00%) |
Mkt cap ! $49.19M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.4¢ | 1.2¢ | $176.4K | 13.57M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 5353143 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 493343 | 1 |
View Market Depth
| Last trade - 15.45pm 13/09/2024 (20 minute delay) ? |
| OSL (ASX) Chart |